151 related articles for article (PubMed ID: 17373906)
1. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy.
Tolmachev V; Orlova A; Nilsson FY; Feldwisch J; Wennborg A; Abrahmsén L
Expert Opin Biol Ther; 2007 Apr; 7(4):555-68. PubMed ID: 17373906
[TBL] [Abstract][Full Text] [Related]
2. Update: affibody molecules for molecular imaging and therapy for cancer.
Orlova A; Feldwisch J; Abrahmsén L; Tolmachev V
Cancer Biother Radiopharm; 2007 Oct; 22(5):573-84. PubMed ID: 17979560
[TBL] [Abstract][Full Text] [Related]
3. Radionuclide molecular imaging using Affibody molecules.
Ahlgren S; Tolmachev V
Curr Pharm Biotechnol; 2010 Sep; 11(6):581-9. PubMed ID: 20497119
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules.
Ahlgren S; Orlova A; Rosik D; Sandström M; Sjöberg A; Baastrup B; Widmark O; Fant G; Feldwisch J; Tolmachev V
Bioconjug Chem; 2008 Jan; 19(1):235-43. PubMed ID: 18163536
[TBL] [Abstract][Full Text] [Related]
5. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
6. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
7. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.
Tran T; Engfeldt T; Orlova A; Widström C; Bruskin A; Tolmachev V; Karlström AE
Bioconjug Chem; 2007; 18(2):549-58. PubMed ID: 17330952
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with (18)F-4-fluorobenzaldehyde.
Rosik D; Thibblin A; Antoni G; Honarvar H; Strand J; Selvaraju RK; Altai M; Orlova A; Eriksson Karlström A; Tolmachev V
Bioconjug Chem; 2014 Jan; 25(1):82-92. PubMed ID: 24344772
[TBL] [Abstract][Full Text] [Related]
9. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
10. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
[TBL] [Abstract][Full Text] [Related]
11. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition.
Tolmachev V; Tran TA; Rosik D; Sjöberg A; Abrahmsén L; Orlova A
J Nucl Med; 2012 Jun; 53(6):953-60. PubMed ID: 22586147
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging.
Honarvar H; Jokilaakso N; Andersson K; Malmberg J; Rosik D; Orlova A; Karlström AE; Tolmachev V; Järver P
Nucl Med Biol; 2013 Apr; 40(3):378-86. PubMed ID: 23357083
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.
Andersson KG; Rosestedt M; Varasteh Z; Malm M; Sandström M; Tolmachev V; Löfblom J; Ståhl S; Orlova A
Oncol Rep; 2015 Aug; 34(2):1042-8. PubMed ID: 26059265
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting.
Altai M; Perols A; Tsourma M; Mitran B; Honarvar H; Robillard M; Rossin R; ten Hoeve W; Lubberink M; Orlova A; Karlström AE; Tolmachev V
J Nucl Med; 2016 Mar; 57(3):431-6. PubMed ID: 26659353
[TBL] [Abstract][Full Text] [Related]
15. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.
Tolmachev V; Feldwisch J; Lindborg M; Baastrup B; Sandström M; Orlova A
Nucl Med Biol; 2011 Jul; 38(5):697-706. PubMed ID: 21718945
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.
Mume E; Orlova A; Larsson B; Nilsson AS; Nilsson FY; Sjöberg S; Tolmachev V
Bioconjug Chem; 2005; 16(6):1547-55. PubMed ID: 16287254
[TBL] [Abstract][Full Text] [Related]
17. Imaging of HER-2 overexpression in tumors for guiding therapy.
Tolmachev V
Curr Pharm Des; 2008; 14(28):2999-3019. PubMed ID: 18991715
[TBL] [Abstract][Full Text] [Related]
18. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.
Tolmachev V; Altai M; Sandström M; Perols A; Karlström AE; Boschetti F; Orlova A
Bioconjug Chem; 2011 May; 22(5):894-902. PubMed ID: 21443270
[TBL] [Abstract][Full Text] [Related]
20. Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga- compared to 111in-labeled conjugates.
Honarvar H; Strand J; Perols A; Orlova A; Selvaraju RK; Eriksson Karlström A; Tolmachev V
Mol Imaging; 2014; 13():. PubMed ID: 25249017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
